日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Development of leading first-generation vaccines against SARS-CoV-2

针对SARS-CoV-2的领先第一代疫苗的研发

Perera, Pin-Yu; Perera, Liyanage P

Inclusion of an E7 DNA Amplification Test Improves the Robustness of Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma Diagnosis

纳入 E7 DNA 扩增测试可提高人乳头瘤病毒相关口咽鳞状细胞癌诊断的稳健性

Pin-Yu Perera, Liyanage P Perera, Lyvouch Filkoski, Wen Chen, Jack H Lichy, Edina Paal, Jessica H Maxwell

Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies

靶向趋化因子受体CCR4的嵌合抗原受体修饰T细胞可作为T细胞恶性肿瘤的治疗手段

Liyanage P Perera ,Meili Zhang ,Masao Nakagawa ,Michael N Petrus ,Michiyuki Maeda ,Marshall E Kadin ,Thomas A Waldmann ,Pin-Yu Perera

Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease

托法替尼是一种 Janus 激酶抑制剂,在重现乳糜泻病理表现的 IL-15 转基因小鼠模型中显示出疗效

Seiji Yokoyama, Pin-Yu Perera, Thomas A Waldmann, Takachika Hiroi, Liyanage P Perera

Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice

以痘苗病毒为基础的多价 H5N1 禽流感疫苗添加 IL-15 佐剂可为小鼠提供无菌跨进化枝保护

Leo L M Poon, Y H Connie Leung, John M Nicholls, Pin-Yu Perera, Jack H Lichy, Masafumi Yamamoto, Thomas A Waldmann, J S Malik Peiris, Liyanage P Perera